News | Women's Health | October 11, 2017

National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment

Washington, D.C., breast surgeon identifies key technologies making an impact in the fight against breast cancer today

National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment

October 11, 2017 — In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the second leading cause of death in women, according to the American Cancer Society. Advances in technology continue to become available to aid in the fight against breast cancer which can improve the chances of beating the disease. David Weintritt, M.D., founder of the National Breast Center and National Breast Center Foundation, recently identified the top three technologies impacting the future of breast cancer treatment to improve outcomes for women diagnosed with the disease.

1. BioZorb, created by Focal Therapeutics, is a three-dimensional implantable device used in women with breast cancer undergoing breast conserving surgery or lumpectomy. It provides a clear target for more precise radiation therapy, which lowers risk of cancer recurrence while often lowering the overall radiation dose as well. This device also allows surgeons to better reshape the breast providing cosmetic advantages as well. BioZorb allows surgeons to improve outcomes by reducing errors in radiation planning while maintaining a healthier, more natural appearance.

2. Mammaprint, made by Agendia, is a genomic test that analyzes the genetic code of breast cancer cells, giving a more accurate measurement of recurrence risk. Traditional methods used to determine the risk of cancer recurrence lead to many women with early-stage breast cancer receiving chemotherapy. The Mammaprint 70-Gene Assay is the only U.S. Food and Drug Administration (FDA)-cleared test that provides a personalized, definitive result so the patient can know with certainty if they are at low risk for cancer relapse – and not likely to benefit from chemotherapy. Unlike other tests, users are given definitive Low Risk and High Risk results, eliminating the uncertainty of an intermediate risk score. These results, in addition to all other factors help patients and their doctors make the most appropriate breast cancer treatment decisions.

3. SPY Portable Handheld Imager (SPY-PHI), manufactured by Novadaq and FDA-approved, utilizes SPY Fluorescence Imaging Technology that allows surgeons to visualize blood flow and related tissue perfusion in real time, reducing surgical complications and increasing reconstruction options for patients. This can be used during plastic, microsurgical, reconstructive and gastrointestinal procedures.

“Advances in technology for breast cancer are not always known to patients, so they may feel as though their options are limited,” said Weintritt. “It’s critical that patients are educated about their options so they can be informed, proactive and have the best outcomes possible. What we do know is that Washington, D.C., is leading the nation in both breast cancer incidence rates and breast cancer mortality rates, and currently the majority of women with breast cancer are not hearing about options that are proven useful in treating breast cancer. Its innovations such as these and commitment to using them to create a personalized treatment plan that can truly make a difference in the lives of breast cancer patients so it’s critical we spread the word.”

For more information: www.nationalbreastcenter.com

Related Women's Health Content

Research Finds Surgical Marker Helps Cut Cost of Breast Cancer Treatment

Related Content

Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
Qfix kVue One Proton Couch Top Validated by Mevion Medical Systems
News | Patient Positioning Radiation Therapy | August 07, 2019
Qfix and Mevion Medical Systems announced that a special version of the kVue One Proton couch top is now both validated...
IBA Signs Contract to Install Proton Therapy Center in Kansas
News | Proton Therapy | August 06, 2019
IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution...